Curemark said it has reached its target of enrolling 170 patients in this autism drug trial.
Curemark medical director Bill Gannon said they have been extremely pleased with the enthusiastic response of the clinical sites during the CM-AT Phase III trial process.
Curemark’s autism therapy has received Fast Track review status from the FDA.
"We now have the full complement of trial participants and will close the trial to enrollment and begin the compilation process for FDA submissions," Gannon said.
Curemark founder and CEO Joan Fallon said this marks a significant milestone for them and their research program.